Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ selected hematopoietic stem cells
- Development stage
- Phase 2
- Lead developer
- Stanford University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ selected hematopoietic stem cells are an investigational cell therapy product developed at Stanford University for use in haploidentical hematopoietic stem cell transplantation (HSCT). The therapy involves the positive selection of CD34+ progenitor cells from a half-matched (haploidentical) donor, which effectively depletes the graft of T-cells to minimize the risk of graft-versus-host disease (GvHD). This approach is specifically evaluated in older or medically unfit patients with various hematologic malignancies, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia, as well as severe aplastic anemia. The transplantation protocol utilizes a non-myeloablative conditioning regimen consisting of total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG), designed to promote stable donor engraftment and a graft-versus-tumor effect with reduced toxicity compared to traditional myeloablative regimens.
- Other names
- Haploidentical CD34+ selected hematopoietic cellsCD34+ selected peripheral blood stem cellsCD34+ selected HSCs
Beyond the preview
Go deeper on CD34+ selected hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ selected hematopoietic stem cells.